Differential expression of elafin in human normal mammary epithelial cells and carcinomas is regulated at the transcriptional level.

Elafin is an elastase inhibitor with a unique structure, not related to the serpin family, which includes the neutrophil elastase inhibitor. The gene was identified in this laboratory by subtractive hybridization between RNAs from human mammary tumor-derived cells and cDNAs from normal human mammary epithelial cells. Elafin is consistently expressed in normal mammary epithelial cells, but is down-regulated in most breast tumor cell lines. Restriction fragment analysis detected no gross deletions or rearrangement of the gene in any of the tumor cell lines examined. The elafin gene was cloned, and both the cDNA and the promoter region were sequenced. A major positive upstream promoter element was identified by chloramphenicol acetyltransferase assay and deletion analysis, active in normal cell extracts but not in extracts of tumor cells. These results demonstrate that differential expression of elafin in normal mammary epithelial cells and breast tumor cells is regulated at the transcriptional level. Cell synchronization experiments demonstrated that elafin mRNA is down-regulated in S phase in normal cells. These results suggest that elafin may act as an inhibitor of cell cycle progression.

[1]  Y. Suzuki,et al.  Elastase inhibitor elafin is a new type of proteinase inhibitor which has a transglutaminase-mediated anchoring sequence termed "cementoin". , 1994, Journal of biochemistry.

[2]  H. Tsou,et al.  Down-Regulation of Retinoic Acid Receptor 3 in Mammary Carcinoma Cell Lines and Its Up-Regulation in Senescing Normal Mammary Epithelial Cells 1 , 2005 .

[3]  J. Schalkwijk,et al.  Differential expression of SKALP/Elafin in human epidermal tumors. , 1993, The American journal of pathology.

[4]  B. Wieringa,et al.  SKALP/elafin: an elastase inhibitor from cultured human keratinocytes. Purification, cDNA sequence, and evidence for transglutaminase cross-linking. , 1993, The Journal of biological chemistry.

[5]  R. Schimke,et al.  In vivo inhibition of cyclin B degradation and induction of cell-cycle arrest in mammalian cells by the neutral cysteine protease inhibitor N-acetylleucylleucylnorleucinal. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[6]  H. Yoshioka,et al.  Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation. , 1993, Cancer research.

[7]  Wen‐Tien Chen Membrane proteases: Roles in tissue remodeling and tumour invasion , 1992, Current Biology.

[8]  K. Keyomarsi,et al.  Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. , 1991, Cancer research.

[9]  L. Liotta,et al.  Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.

[10]  O. Wiedow,et al.  Elafin is a potent inhibitor of proteinase 3. , 1991, Biochemical and biophysical research communications.

[11]  P. Chambon,et al.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.

[12]  M. Duffy,et al.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. , 1990, Cancer research.

[13]  J. Schröder,et al.  Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. , 1990, The Journal of biological chemistry.

[14]  V. Band,et al.  Distinctive traits of normal and tumor-derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[15]  B. Howard,et al.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells , 1982, Molecular and cellular biology.